Peter Sever is Professor of Clinical Pharmacology and Therapeutics at Imperial College London, Honorary Consultant Physician at the Imperial Healthcare NHS Trust and Co-Director of the International Centre for Circulatory Health.
After graduating from Cambridge, Professor Sever completed his training at St Mary’s Hospital Medical School. Following a succession of appointments in general medicine, cardiology and chest diseases, followed by lectureships in medicine and pharmacology, he became an Honorary Consultant Physician and Senior Lecturer in Medicine in the Medical Unit at St Mary’s Hospital in 1976. In 1980 he was appointed Professor of Clinical Pharmacology and Therapeutics at St Mary’s Hospital Medical School, which was subsequently incorporated into the Imperial College School of Medicine.
During the past decade he established a major research programme in the pathogenesis and treatment of cardiovascular disease. He is Joint Editor in Chief of the Journal of the Renin-Angiotensin-Aldosterone System. He has been a member of the editorial boards of several journals, including the Journal of Hypertension, Journal of Human Hypertension and Clinical Science. Professor Sever is a past-president of the British Hypertension Society (1989-1991) and past president of the European Council for Blood Pressure and Cardiovascular Research. He is also a Fellow of the European Society of Cardiology and past Chairman of the Fellowships Committee of the British Heart Foundation. He received the Astra-Zeneca Award from the International Society for Hypertension in 2010 for contributions to the clinical pharmacology of hypertension. In 2011, he gave the Sir George Pickering Lecture to the British Hypertension Society, and was elected as Honorary Fellow of Trinity Hall, Cambridge.
His current research interests in cardiovascular disease include the pathophysiology of vascular disease, the evaluation of anti-hypertensive drug therapy and multiple risk factor intervention in hypertensive populations. He was the Co-Chairman of the Anglo-Scandinavian Cardiac Outcomes Trial, which defined the role of optimal treatment strategies for blood pressure lowering and the role of lipid lowering in the primary prevention of cardiovascular disease in hypertensive patients. He is currently a member of the Executive Committee for the Fourier Trial, one of the first studies investigating the potential benefits of a monoclonal antibody to PCSK9 in the prevention of recurrent cardiovascular events in patients with established cardiovascular disease. He is also interested in the epidemiology of hypertension with particular reference to environmental influences on blood pressure, and ethnic differences.
et al., 2018, Novel genetic associations for blood pressure identified via gene-alcohol interaction in up to 570K individuals across multiple ancestries., Plos One, Vol:13
et al., 2018, Comparison of Low-density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial., Jama Cardiol
et al., 2018, Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies, Lancet Diabetes & Endocrinology, Vol:6, ISSN:2213-8587, Pages:464-475
et al., 2018, Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER., Circulation
et al., 2018, Inflammatory and Cholesterol Risk in the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk)., Circulation